2. Inflammation/Immunology

Inflammation/Immunology

Inflammation/Immunology

Related Products

PDF 93.1 MB

The diseases caused by disorders of the immune system fall into two broad categories: immunodeficiency and autoimmunity. Immunotherapy is also often used in the immunosuppressed (such as HIV patients) and people suffering from other immune deficiencies or autoimmune diseases. This includes regulating factors such as IL-2, IL-10, IFN-α. Infection with HIV is characterized not only by development of profound immunodeficiency but also by sustained inflammation and immune activation. Chronic inflammation as a critical driver of immune dysfunction, premature appearance of aging-related diseases, and immune deficiency.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-141420
    PtdIns-(3,4,5)-P3(1,2-dihexanoyl) ammonium 799268-62-5 98%
    PtdIns-(3,4,5)-P3(1,2-dihexanoyl) ammonium (compound 850176) is a vaccine adjuvant that enhances the immune function of vaccines.
    PtdIns-(3,4,5)-P3(1,2-dihexanoyl) ammonium
  • HY-141439
    TBE 31 936475-62-6 98%
    TBE 31 is an orally active Keap1/Nrf2 pathway activator and NQO1 inducer with a Dm value of 1.1 nM for NQO1. TBE 31 binds to cysteine residues of Keap1, inhibits ubiquitination and degradation of Nrf2, thereby activating the expression of ARE-dependent genes. TBE 31 induces cytoprotective enzymes including NQO1 and GST isoforms, promotes Nrf2 accumulation, and upregulates Nrf2-regulated genes related to antioxidation and lipid metabolism. TBE 31 inhibits pro-inflammatory responses, formation of AFB1-DNA adducts, endoplasmic reticulum stress, cell apoptosis (apoptosis), hepatic fibrosis, oxidative stress, and the expression of ChREBP. TBE 31 reduces the number of tumors in a mouse model of ultraviolet-induced skin carcinogenesis. TBE 31 enhances nerve growth factor-induced neurite outgrowth. TBE 31 attenuates LPS-induced serum TNF-α levels and immobility time in mice. TBE 31 can be used in research related to liver cancer, skin cancer, inflammation-related depression, and non-alcoholic steatohepatitis.
    TBE 31
  • HY-141535
    IL-17 modulator 1 2446803-85-4 98%
    IL-17 modulator 1 is an orally active, highly efficacious small molecule IL-17 modulators extracted from patent WO 2020127685. IL-17 modulator 1 can be used for the research of preventing, researching or ameliorating a variety of diseases including psoriasis, ankylosing spondylitis and psoriatic arthritis.
    IL-17 modulator 1
  • HY-141547
    Nav1.7-IN-8 1432913-44-4 98%
    Nav1.7-IN-8 is a potent blockage of NaV1.7 with high selectivity for the inhibition of NaV1.7 over the subtypes hNaV1.1 and hNaV1.5. Nav1.7-IN-8 inhibits CYP2C9 and CYP3A4 with an IC50 of 0.17 μM and 0.077 μM, respectively. Nav1.7-IN-8 displays significant analgesic effects in rodent models of acute and inflammatory pain.
    Nav1.7-IN-8
  • HY-14157A
    ADL-5747 hydrochloride 1187653-56-0 98%
    ADL-5747 hydrochloride is a selective and orally active agonist of the δ-opioid receptor (DOR). By binding to the δ-opioid receptors, ADL-5747 hydrochloride activates these receptors, thereby playing a role in pain management pathways. ADL-5747 hydrochloride can be used for research into pain management mechanisms.
    ADL-5747 hydrochloride
  • HY-14164R
    Zileuton (Standard) 111406-87-2 98%
    Zileuton (Standard) is the analytical standard of Zileuton. This product is intended for research and analytical applications. Zileuton is a potent and selective inhibitor of 5-lipoxygenase with antiasthmatic properties.
    Zileuton (Standard)
  • HY-14164S
    Zileuton-d4 1189878-76-9 98%
    Zileuton-d4 is the deuterium labeled Zileuton. Zileuton (A 64077) is a potent and selective inhibitor of 5-lipoxygenase with antiasthmatic properties.
    Zileuton-d4
  • HY-141662
    2',3'-cGAMP-C2-PPA 2586047-11-0
    2’,3’-cGAMP-C2-PPA is a cyclic dinucleotide interferon gene-stimulating protein (STING) agonist. 2’,3’-cGAMP-C2-PPA is a drug conjugated conjugate used to target antibody-drug conjugated conjugate (ADC) for the treatment of cancer. 2’,3’-cGAMP-C2-PPA can be used in the study of immune and tumor-related diseases.
    2',3'-cGAMP-C2-PPA
  • HY-141713
    ZA10 2696407-24-4 98%
    ZA10 is a selective TRPM2 channel inhibitor, with an IC50 value of 8.1 μM. ZA10 can effectively suppress intracellular Ca2+ overload triggered by TRPM2 channel activation. ZA10 significantly reduce the mortality of SH-SY5Y cells induced by H2O2. ZA10 can be used for the study of ischemia-reperfusion injury, inflammation, or other neurodegenerative diseases.
    ZA10
  • HY-141843
    BRD4-IN-2 2679925-55-2 98%
    BRD4-IN-2 is a bromodomain BRD4 inhibitor with an IC50 value of 9.9 nM.
    BRD4-IN-2
  • HY-141864
    ITK/TRKA-IN-1 2655557-54-1 98%
    ITK/TRKA-IN-1 is a dual inhibitor of IL-2-inducible T-cell kinase (ITK) and tropomyosin receptor kinase A (TRKA) with an IC50 value of 1.0 nM and 96 % inhibition, respectively.
    ITK/TRKA-IN-1
  • HY-142032
    RBM10-8 2407372-42-1 98%
    RBM10-8 is irreversible inhibitor of recombinant  human sphingosine-1-phosphate lyase (hS1PL) . Sphingosine-1-phosphate (S1P) is a sphingolipid (SL) that acts as a signaling molecule regulating diverse cellular processes such as cell proliferation and differentiation, angiogenesis, immune function, inflammation, and development.
    RBM10-8
  • HY-142100
    Licoagrochalcone C 325144-68-1
    Licoagrochalcone C, a flavonoid, reveals efficacious inhibitory activity on NF-κB transcription. Licoagrochalcone C shows significant inhibitory activity on LPS (HY-D1056)-induced NO production.
    Licoagrochalcone C
  • HY-142644
    ATX inhibitor 7 1646784-47-5 98%
    ATX inhibitor 7 is a autotaxin inhibitor and shows good oral exposure.
    ATX inhibitor 7
  • HY-142676
    PI3K-IN-26 1918151-65-1 98%
    PI3K-IN-26 is a potent PI3K inhibitor with an IC50 of 36 nM for SU-DHL-6 cells (WO2016066142A1, compound 1).
    PI3K-IN-26
  • HY-142677
    PI3K-IN-27 2742654-38-0 98%
    PI3K-IN-27 is a potent inhibitor of PI3K. PI3K belongs to a large family of lipid signaling kinase that plays key role in cellular process including cell growth, differentiation, migration and apoptosis. PI3K-IN-27 has the potential for the research of hyper-proliferative diseases like cancer and inflammation, or immune and autoimmune diseases (extracted from patent WO2021233227A1, compound 1).
    PI3K-IN-27
  • HY-142686
    SGK1-IN-3 2891696-18-5 98%
    SGK1-IN-3 (Compound 3a) is an ATP-competitive SGK1 inhibitor with an IC50 of <1 nM against hSGK1. SGK1-IN-3 blocks the activity of CDK family members. SGK1-IN-3 is a P-glycoprotein substrate. SGK1-IN-3 can be used for research on osteoarthritis.
    SGK1-IN-3
  • HY-142703
    RORγt inverse agonist 28 2741870-21-1 98%
    RORγt inverse agonist 28 is a potent reverse agonist of RORγt. RORγt inverse agonist 28 regulates the differentiation of Th17 cells and inhibits the production of IL-17. RORγt inverse agonist 28 has the potential for the research of inflammation and autoimmune diseases (extracted from patent WO2021228215A1, compound 6) .
    RORγt inverse agonist 28
  • HY-142834
    RORγt/DHODH-IN-2 2641758-86-1 98%
    RORγt/DHODH-IN-2 (compound 1) is a potent dual RORγt/DHODH inhibitor. RORγt/DHODH-IN-2 can be used for inflammatory bowel disease (IBD) research.
    RORγt/DHODH-IN-2
  • HY-142843
    RORγt/DHODH-IN-1 2764662-15-7 98%
    RORγt/DHODH-IN-1 (compound (R)-14d) is a potent and orally active dual RORγt/DHODH inhibitor, with IC50s of 0.083 μM and 0.172 μM, respectively. RORγt/DHODH-IN-1 exhibits remarkable in vivo anti-inflammatory activity.
    RORγt/DHODH-IN-1
Cat. No. Product Name / Synonyms Application Reactivity